| 5.55 0.05 (0.91%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.73  |
1-year : | 7.87 |
| Resists | First : | 5.76 |
Second : | 6.73 |
| Pivot price | 4.95 |
|||
| Supports | First : | 4.67 |
Second : | 4 |
| MAs | MA(5) : | 5.39 |
MA(20) : | 4.77 |
| MA(100) : | 10.02  |
MA(250) : | 9.12 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 87.5 |
D(3) : | 87.8 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 21.87 | Low : | 3.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MGNX ] has closed below upper band by 16.1%. Bollinger Bands are 69.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.78 - 5.8 | 5.8 - 5.82 |
| Low: | 5.4 - 5.42 | 5.42 - 5.45 |
| Close: | 5.51 - 5.54 | 5.54 - 5.59 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Thu, 25 Jul 2024
91,800 Shares in MacroGenics, Inc. (NASDAQ:MGNX) Acquired by Swiss National Bank - Defense World
Wed, 24 Jul 2024
MacroGenics (MGNX) Investigating Three of Five Patient - GlobeNewswire
Mon, 22 Jul 2024
Acadian Asset Management LLC Has $6.97 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - MarketBeat
Mon, 22 Jul 2024
BNP Paribas Financial Markets Sells 6,796 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Mon, 24 Jun 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX - PR Newswire
Mon, 13 May 2024
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 113.1 (%) |
| Shares Short | 7,880 (K) |
| Shares Short P.Month | 9,910 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | -53.6 % |
| Operating Margin | -590.5 % |
| Return on Assets (ttm) | -38.8 % |
| Return on Equity (ttm) | -21.6 % |
| Qtrly Rev. Growth | -62.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.69 |
| EBITDA (p.s.) | -2.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -14.61 |
| PEG Ratio | 0 |
| Price to Book value | 3.26 |
| Price to Sales | 8.01 |
| Price to Cash Flow | -3.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|